Pralsetinib and selpercatinib are RET inhibitors that have been approved based on the results of two phase 1/2 studies: they showed a remarkable intracranial activity and significantly improved clinical outcome of RET-rearranged advanced NSCLC patients, both after the failure of a platinum-based treatment and as first-line treatment [3–5]. This evidence concerns the gene RET and non-small cell lung carcinoma.